Opaleye Management Inc. Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001595855

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q4 2023 · 45 positions · Total reported value $373.15M · Top-10 concentration 63.1% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 50.0% · 13 new · 12 cut · 8 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +40.3% · vs SPY +25.5% · Prev Value $739.73M — last quarter positions weighted by this quarter price moves · ranking

In its Q4 2023 13F filing, Opaleye Management Inc. disclosed 45 equity positions with a combined reported value of $373.15M. The filing implies a focused portfolio: its ten largest positions account for 63.1% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q4 2023 were HROW ($42.78M), TGTX ($37.83M), SLRN ($30.93M). By sector, the heaviest allocations are Health Care 74.3%, Industrials 2.5%. Versus the prior quarter, allocation shifted toward Health Care (+6.2pp), Industrials (+1.8pp) and away from Other (-7.9pp).

Versus the prior quarter, Opaleye Management Inc. opened 13 new positions, trimmed 12 and fully exited 8, a turnover rate of 50.0% of positions. The portfolio's overlap with the prior quarter was 62% of names.

The largest new positions opened in Q4 2023 were ARVN ($10.85M), ARQT ($6.33M), JSPR ($3.14M).

Of the 8 positions fully exited versus the prior quarter, the largest were TELA ($6.00M), GERN ($4.06M), IGMS ($2.18M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q4 2023)

  • ARVN ARVINAS INC · $10.85M
  • ARQT ARCUTIS BIOTHERAPEUTICS INC · $6.33M
  • JSPR JASPER THERAPEUTICS INC · $3.14M
  • NTLA Intellia Therapeutics, Inc. · $3.02M
  • NAMS NEWAMSTERDAM PHARMA COMPANY · $2.96M
  • VTYX VENTYX BIOSCIENCES INC · $2.82M
  • SYRS SYROS PHARMACEUTICALS INC · $2.80M
  • PTGX Protagonist Therapeutics Inc · $2.58M

Fully Exited (vs previous quarter)

  • TELA TELA BIO INC COM · prev qtr: $6.00M
  • GERN GERON CORP · prev qtr: $4.06M
  • IGMS IGM BIOSCIENCES INC · prev qtr: $2.18M
  • TCON TRACON PHARMACEUTICALS I · prev qtr: $848.08K
  • XERS XERIS BIOPHARMA HOLDINGS INC · prev qtr: $725.40K
  • FBIO FORTRESS BIOTECH INC · prev qtr: $580.60K · history
  • KZR KEZAR LIFE SCIENCES INC · prev qtr: $505.75K

Insider Transactions (Form 4)

Latest Opaleye Management Inc. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-11-05 Buy Grace Therapeutics, Inc. 3,087 $1.77 SEC filing
2026-11-04 Buy Grace Therapeutics, Inc. 5,027 $1.80 SEC filing
2026-11-03 Buy Grace Therapeutics, Inc. 10,328 $1.79 SEC filing
2026-10-26 Buy Grace Therapeutics, Inc. 66,411 $1.77 SEC filing
2026-10-23 Buy Alpha Cognition Inc. 14,973 $8.23 SEC filing
2026-10-22 Buy Alpha Cognition Inc. 17,117 $8.33 SEC filing
2026-10-22 Buy Grace Therapeutics, Inc. 21,390 $1.93 SEC filing
2026-10-19 Buy Grace Therapeutics, Inc. 4,256 $1.88 SEC filing

All insider transactions →

Fund Profile

Opaleye Management Inc. is an SEC-registered 13F filer based in Boston, MA, United States. As of Q2 2026 it reported 58 US equity positions with a combined value of $1.10B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: BOSTON, MA, United States
  • SEC registration: 801-78700 (status: Approved), registered 2013-10-29
  • Regulatory AUM (Form ADV): $802.77M as of 2026-02-19
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 1 private funds, of which 1 hedge funds

Portfolio Structure

  • 58 positions · $1.10B reported value (Q2 2026)
  • Top 10 holdings = 64.8% of reported value
  • Largest position: LQDA (LIQUIDIA CORPORATION) at 17.7%
  • Average position size: $19.04M

Sector Tilt

  • Health Care 90.7%
  • Materials 1.9%
  • Industrials 1.4%
  • (classified holdings cover 94% of value)

Quarterly Activity

  • Q2 2026: 13 new, 14 added, 12 reduced, 8 exited
  • 19 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: The fund appears to maintain a cautious approach with a slight inclination towards growth in the healthcare sector. The addition of new positions in healthcare companies suggests an optimism in the sector's potential, while reductions in some holdings indicate selectivity and risk management. 2. Key Moves: - Added: IRON (DISC MEDICINE INC) with a significant increase of 103.1% in shares, MGTX (MeiraGTx Holdings plc) with a 67.2% increase in shares. - Reduced: LQDA (LIQUIDIA CORPORATION) by 3.8% in shares, HROW (HARROW INC) by 15.3% in shares. - Hold: The majority of the top holdings, including ETON (ETON PHARMACEUTICALS INC COM), URGN (UROGEN PHARMA LTD), APGE (APOGEE THERAPEUTICS INC), SLGL (Sol-Gel Technologies Ltd), RZLT (REZOLUTE INC), and TGTX (TG THERAPEUTICS INC). 3. Portfolio Structure: - Passive/Active: The rebalancing appears more active, with strategic additions and reductions. - Sector Bias: The healthcare sector is the clear bias, with 10 out of 11 top holdings in healthcare. - Risk Appetite: The fund exhibits a moderate risk appetite, with significant additions to high-growth potential companies but also reductions in certain positions. 4. Per-Holding One-Liner: - LQDA (LIQUIDIA CORPORATION): Develops and commercializes innovative therapies for serious diseases. - ETON (ETON PHARMACEUTICALS INC COM): Focuses on the development of treatments for central nervous system disorders. - HROW (HARROW INC): A biopharmaceutical company focused on the development of treatments for cancer. - IRON (DISC MEDICINE INC): Engages in the research and development of therapies for rare and orphan diseases. - URGN (UROGEN PHARMA LTD): Specializes in the development of therapies for urological conditions. - APGE (APOGEE THERAPEUTICS INC): Focuses on the development of therapies for cancer and other diseases. - MGTX (MeiraGTx Holdings plc): Develops treatments for a range of ophthalmic diseases. - SLGL (Sol-Gel Technologies Ltd): Engages in the development and production of advanced materials and technologies. - RZLT (REZOLUTE INC): Specializes in the development of treatments for rare diseases. - TGTX (TG THERAPEUTICS INC): Focuses on the development of therapies for cancer and other diseases. - Unverified: No unverified holdings noted. 5. One-Sentence Style Summary: The fund maintained a selective approach in healthcare, focusing on growth potential with strategic additions and reductions, while maintaining a cautious stance through sector concentration and selective adjustments.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 74.3%
Other 23.2%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 3.82M $42.78M 11.47%
11.47%
Add
2 2.21M $37.83M 10.14%
10.14%
Add
3 4.15M $30.93M 8.29%
8.29%
Hold
4 610.00K $28.04M 7.51%
7.51%
Reduce
5 6.07M $27.07M 7.25%
7.25%
Reduce
6 1.26M $21.44M 5.75%
5.75%
Add
7 357.50K $14.21M 3.81%
3.81%
Reduce
8 311.50K $11.08M 2.97%
2.97%
Hold
9 2.53M $11.08M 2.97%
2.97%
Add
10 307.50K $10.94M 2.93%
2.93%
Reduce
11 263.70K $10.85M 2.91%
2.91%
New
12 3.05M $9.29M 2.49%
2.49%
Add
13 200.00K $8.56M 2.29%
2.29%
Reduce
14 699.00K $7.65M 2.05%
2.05%
Reduce
15 897.00K $7.29M 1.95%
1.95%
Add
16 1.96M $6.33M 1.70%
1.70%
New
17 308.50K $6.25M 1.68%
1.68%
Hold
18 563.50K $6.13M 1.64%
1.64%
Reduce
19 90.00K $5.65M 1.51%
1.51%
Hold
20 445.00K $5.35M 1.44%
1.44%
Reduce
21 2.69M $5.05M 1.35%
1.35%
Hold
22 320.00K $4.80M 1.29%
1.29%
Hold
23 250.00K $4.62M 1.24%
1.24%
Reduce
24 1.09M $3.66M 0.98%
0.98%
Add
25 877.00K $3.63M 0.97%
0.97%
Add
26 496.50K $3.61M 0.97%
0.97%
Add
27 2.54M $3.40M 0.91%
0.91%
Add
28 3.99M $3.14M 0.84%
0.84%
New
29 99.00K $3.02M 0.81%
0.81%
New
30 265.39K $2.96M 0.79%
0.79%
New
31 623.50K $2.84M 0.76%
0.76%
Reduce
32 1.14M $2.82M 0.76%
0.76%
New
33 359.37K $2.80M 0.75%
0.75%
New
34 2.98M $2.72M 0.73%
0.73%
Reduce
35 112.70K $2.58M 0.69%
0.69%
New
36 150.00K $1.84M 0.49%
0.49%
Reduce
37 211.40K $1.72M 0.46%
0.46%
Hold
38 344.80K $1.60M 0.43%
0.43%
Reduce
39 145.00K $1.44M 0.39%
0.39%
Reduce
40 1.01M $1.36M 0.36%
0.36%
Add
41 301.49K $1.29M 0.35%
0.35%
New
42 975.00K $1.10M 0.29%
0.29%
New
43 130.00K $877.50K 0.23%
0.23%
New
44 1.30M $861.21K 0.23%
0.23%
New
45 37.50K $640.21K 0.17%
0.17%
New

FAQ

What did Opaleye Management Inc. buy in 2023-Q4?

In its 2023-Q4 13F filing, Opaleye Management Inc. reported 45 equity positions worth $373.15M in aggregate; its largest disclosed positions were HROW ($42.78M), TGTX ($37.83M), SLRN ($30.93M).

How large is Opaleye Management Inc.'s portfolio?

Opaleye Management Inc. reported $373.15M of long equity holdings across 45 positions as of 2023-Q4. Top-10 holdings account for 63.1% of reported value.

What is Opaleye Management Inc.'s investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/opaleye-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →